192 results match your criteria Biomarker research[Journal]


Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm.

Biomark Res 2019 4;7. Epub 2019 Apr 4.

1Center of Excellence in Tissue Engineering, Department of cell biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.

Mesenchymal stem/stromal cells (MSCs) have been demonstrated to hold great potential for the treatment of several diseases. Their therapeutic effects are largely mediated by paracrine factors including exosomes, which are nanometer-sized membrane-bound vesicles with functions as mediators of cell-cell communication. MSC-derived exosomes contain cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-019-0159-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450000PMC
April 2019
1 Read

The association between early neurological deterioration and whole blood purine concentration during acute stroke.

Biomark Res 2019 3;7. Epub 2019 Apr 3.

1NIHR Newcastle Biomedical Research Centre and Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

Background: Early neurological deterioration (END) is common after stroke. Prediction could identify patients requiring additional monitoring and intervention. Purines, breakdown products of adenosine triphosphate which accumulate during acute hypoxia, may reflect the subclinical presence of vulnerable tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0158-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448300PMC

Novel insights into MSC-EVs therapy for immune diseases.

Biomark Res 2019 18;7. Epub 2019 Mar 18.

1Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080 People's Republic of China.

Mesenchymal stromal cells (MSC) are a heterogeneous cell population with self-renewal and the ability to differentiate into different lineages. The novel regulatory role of MSC in both adaptive and innate immune responses got extensive investigation and MSC have been widely used in clinical trials as immunosuppressive agents for autoimmune and inflammatory diseases, including graft-versus-host disease (GVHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), chronic kidney disease, etc. Recent studies have found that MSC exerted their immunomodulation function through secreting extracellular vesicles (EVs), which delivered parent cell cargo to recipient cells without oncogenicity or variability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0156-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423844PMC
March 2019
1 Read

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.

Biomark Res 2019 8;7. Epub 2019 Mar 8.

1Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.

Background: Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker with elevated expression in BE patients with high grade dysplasia and/or EAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0157-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408757PMC
March 2019
5 Reads

The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients.

Biomark Res 2019 22;7. Epub 2019 Feb 22.

1Department of Pathology& Laboratory Medicine, Aga Khan University Hospital (AKUH), Stadium Road, P.O. Box 3500, Karachi, 74800 Pakistan.

In current clinical practice, Serum Creatinine (SCr) is a commonly used marker for the diagnosis of acute kidney injury (AKI). Unfortunately, due to a delayed increase in SCr, it is unable to accurately estimate the timing of the injury. The purpose of this study was to assess the ability of plasma neutrophil gelatinase-associated lipocalin (pNGAL) to predict AKI in critically ill adult patients The study was conducted at the Section of Chemical Pathology, Department of Pathology& Laboratory Medicine in collaboration with Department of Anesthesiology, at Aga Khan University Hospital in Karachi, Pakistan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0155-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387517PMC
February 2019
1 Read

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Biomark Res 2019 12;7. Epub 2019 Feb 12.

1Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia 5042 Australia.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by significant clinical heterogeneity and as such reliable biomarkers are required to measure disease activity and assess treatment response. Recent advances in our understanding of disease pathogenesis and the discovery of novel serum-based, electrophysiologic and imaging biomarkers allow clinicians to make more informed decisions regarding individualised treatment regimes. As a chronic immune-mediated process typified by relapse following withdrawal of immunomodulatory therapy, a substantial proportion of patients with CIDP require long term treatment with intravenous immunoglobulin (IVIg), a scarce and expensive donor-derived resource. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0154-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373155PMC
February 2019

Pluripotency markers are differentially induced by IGF1 and bFGF in cells from patients' lesions of large/giant congenital melanocytic nevi.

Biomark Res 2019 14;7. Epub 2019 Jan 14.

Department of Pathology, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15224 USA.

Factors regulating transcription of pluripotency genes in congenital nevo-melanocytes are not known. Nevo-melanocytes belong somewhere in-between the ends of a spectrum where the normal epidermal melanocyte represents one end and a melanoma cell with multiple genetic abnormalities represents the other. Cells from large/giant congenital nevi (L/GCMN), unlike normal melanocytes, grow colonies on soft agar and express pluripotency markers, similar to melanoma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0152-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332894PMC
January 2019
9 Reads

Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma.

Biomark Res 2019 14;7. Epub 2019 Jan 14.

1Department of Clinical Sciences Lund, Oncology and Pathology, Lund University, Lund, Sweden.

There is a great unmet clinical need to identify patients with thin primary cutaneous melanomas (T1, Breslow thickness ≤ 1 mm) who have a high risk for tumour recurrence and death from melanoma. Kin of IRRE-like protein 1 (KIRREL/NEPH1) is expressed in podocytes and involved in glomerular filtration. Screening in the Human Protein Atlas portal revealed a particularly high expression of KIRREL in melanoma, both at the mRNA and protein levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0153-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332842PMC
January 2019
2 Reads

Reduced nuclear DNA methylation and mitochondrial transcript changes in adenomas do not associate with mtDNA methylation.

Biomark Res 2018 29;6:37. Epub 2018 Dec 29.

1Department of Pharmacology, School of Medical Sciences, UNSW Sydney, Sydney, NSW Australia.

Background: Altered mitochondrial function and large-scale changes to DNA methylation patterns in the nuclear genome are both hallmarks of colorectal cancer (CRC). Mitochondria have multiple copies of a 16 kb circular genome that contains genes that are vital for their function. While DNA methylation is known to alter the nuclear genome in CRC, it is not clear whether it could have a similar influence in mtDNA; indeed, currently, the issue of whether mitochondrial genome (mtDNA) methylation occurs is controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0151-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311003PMC
December 2018
1 Read

The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo.

Biomark Res 2018 7;6:36. Epub 2018 Dec 7.

3Department of Medical Biophysics, University of Toronto, Sunnybrook Research Institute, Toronto, ON M4N 3M5 Canada.

Background: In patients with myelodysplastic syndrome (MDS), bone marrow cells have an increased predisposition to apoptosis, yet MDS cells outcompete normal bone marrow (BM)-- suggesting that factors regulating growth potential may be important in MDS. We previously identified v-Erb A related-2 (EAR-2, NR2F6) as a gene involved in control of growth ability.

Methods: Bone marrow obtained from C57BL/6 mice was transfected with a retrovirus containing EAR-2-IRES-GFP. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0149-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286615PMC
December 2018
12 Reads

hypermethylated in a subset of patients with metaplastic changes in their esophagus.

Biomark Res 2018 7;6:35. Epub 2018 Dec 7.

4School of Medical Sciences, Faculty of Medicine, UNSW Sydney, Kensington, NSW 2052 Australia.

hypermethylation is considered a promising cancer biomarker. We examined methylation levels in the first exon of in two patient cohorts within the esophageal adenocarcinoma and gastric adenocarcinoma cascades and in a range of cell-lines using a custom PyroMark CpG assay. Methylation levels were significantly higher in esophageal tissue with histologically confirmed glandular mucosa as compared to tissue from normal esophagi or gastro-esophageal reflux disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0150-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286609PMC
December 2018
1 Read

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.

Biomark Res 2018 7;6:34. Epub 2018 Dec 7.

1Laboratory medicine program, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street, 11th floor, Toronto, ON M5G 2C4 Canada.

Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is of great interest in human cancer. It has been shown to have a dual nature, as it can act as a gene repressor or activator. Studies have highlighted the various roles of EZH2 in the pathophysiology of multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0148-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286605PMC
December 2018

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Biomark Res 2018 21;6:33. Epub 2018 Nov 21.

6Department of Clinical Science, University of Bergen, Bergen, Norway.

Background: A feature of myeloproliferative neoplasia is transforming to more aggressive and malignant myeloid neoplasia, including acute myeloid leukemia. Different pathogenesis mechanisms participate in transformation, including transformation of existing potential preleukemic clones, since -mutant myeloproliferative neoplasms often transform to wild-type acute myeloid leukemia.

Case Presentation: Here, we present an 80 year old man with a -V617F mutant primary myelofibrosis. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0147-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249888PMC
November 2018
16 Reads

Molecular landscape and targeted therapy of acute myeloid leukemia.

Biomark Res 2018 8;6:32. Epub 2018 Nov 8.

Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020 People's Republic of China.

For decades, genetic aberrations including chromosome and molecular abnormalities are important diagnostic and prognostic factors in acute myeloid leukemia (AML). ATRA and imatinib have been successfully used in AML and chronic myelogenous leukemia, which proved that targeted therapy by identifying molecular lesions could improve leukemia outcomes. Recent advances in next generation sequencing have revealed molecular landscape of AML, presenting us with many molecular abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0146-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225571PMC
November 2018
1 Read

Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts.

Biomark Res 2018 30;6:31. Epub 2018 Oct 30.

1Department of Morphology, Surgery and Experimental Medicine, LTTA Centre, University of Ferrara, 44121 Ferrara, Italy.

Background: We aim to characterize the heterogeneous circulating tumour cells (CTCs) in peripheral blood, independently of physical or immunological purification, by using patient-derived xenografts (PDXs) models. CTC studies from blood generally rely on enrichment or purification. Conversely, we devised a method for the inclusive study of human cells from blood of PDX models, without pre-selection or enrichment. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0145-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208170PMC
October 2018
16 Reads

Overexpression and cytoplasmic localization of caspase-6 is associated with lamin A degradation in set of ovarian cancers.

Biomark Res 2018 30;6:30. Epub 2018 Oct 30.

2Sylvester Cancer Center (SCCC), Ovarian Cancer Program, University of Miami, Miami, Florida USA.

Background: In most women with ovarian cancer, the diagnosis occurs after dissemination of tumor cells beyond ovaries. Several molecular perturbations occur ahead of tumor initiation including loss of lamin A/C. Our hypothesis was that the loss of nuclear structural proteins A type lamins (lamin A/C) transcribed from LMNA gene and substrate for active caspase-6 maybe one of the molecular perturbations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0144-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208109PMC
October 2018

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.

Biomark Res 2018 26;6:29. Epub 2018 Sep 26.

1Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY USA.

Recurrent gene mutations have been described with varying frequencies in myelodysplasia (MDS) /myeloproliferative neoplasm (MPN) overlap syndromes (MMOS). Recent work has placed significant focus on understanding the role of gene lesions involving the spliceosomal machinery in leukemogeneis. SRSF2 is a gene encoding critical spliceosomal proteins. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0142-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158887PMC
September 2018
7 Reads

Aptamer-based search for correlates of plasma and serum water T: implications for early metabolic dysregulation and metabolic syndrome.

Biomark Res 2018 17;6:28. Epub 2018 Sep 17.

1Nanoparticle Diagnostics Laboratory, Institute for Cardiovascular & Metabolic Diseases, University of North Texas Health Science Center, Fort Worth, TX 76107 USA.

Background: Metabolic syndrome is a cluster of abnormalities that increases the risk for type 2 diabetes and atherosclerosis. Plasma and serum water T from benchtop nuclear magnetic resonance relaxometry are early, global and practical biomarkers for metabolic syndrome and its underlying abnormalities. In a prior study, water T was analyzed against ~ 130 strategically selected proteins and metabolites to identify associations with insulin resistance, inflammation and dyslipidemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0143-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142358PMC
September 2018
3 Reads

Dysregulated transcriptional networks in and -rearranged T-ALL.

Biomark Res 2018 23;6:27. Epub 2018 Aug 23.

2Department of Pediatrics, University of New Mexico, MSC105590, Albuquerque, NM 87131 USA.

For children and young adults with T-lineage acute lymphoblastic leukemia (T-ALL), event free survival following relapse is < 10%. We recently showed that rearrangements of the mixed lineage leukemia gene (-R) are associated with induction failure and an inferior survival in T-ALL. Because there are currently no molecular features that inform treatment strategies in T-ALL, we hypothesized that transcriptional alterations related to and T-ALL could identify biologically relevant genes and signaling pathways for the development of targeted therapies for these groups of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0141-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107954PMC
August 2018
13 Reads

Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia.

Biomark Res 2018 9;6:26. Epub 2018 Aug 9.

Department of Microbiology and Immunology, Des Moines University - College of Osteopathic Medicine, 3200 Grand Avenue, Des Moines, Iowa 50312 USA.

Background: Aggressive natural killer cell leukemia is a devastating disease, with an average patient survival time of less than 2 months following diagnosis. Due to P-glycoprotein-mediated resistance of the tumor cells most forms of chemotherapy are of limited efficacy, therefore new treatment strategies are needed. Statin drugs have recently been found to inhibit the growth of various tumor cell types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0140-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085711PMC

Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma.

Biomark Res 2018 27;6:25. Epub 2018 Jul 27.

6Department of Pathology, Massachusetts General Hospital, Boston, MA USA.

Background: Diagnosing pancreatic ductal adenocarcinoma (PDAC) in the setting of metastasis with an unknown primary remains very challenging due to the lack of specific biomarkers. HNF-1B has been characterized as an important transcription factor for pancreatic development and was reported as a biomarker for clear cell subtype of PDAC.

Methods: To investigate the diagnostic role of HNF-1B for PDAC, we used tissue microarray (TMA) and immunohistochemistry (IHC) to characterize HNF-1B expression in a large cohort of carcinomas, including 127 primary PDACs, 47 biliary adenocarcinomas, 17 metastatic PDACs, and 231 non-pancreaticobiliary carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0139-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062876PMC
July 2018
22 Reads

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma.

Biomark Res 2018 18;6:24. Epub 2018 Jul 18.

1Section of Virology, Department of Medicine, Imperial College London, W2 1PG, London, UK.

The prognosis of adult T-cell leukemia-lymphoma (ATL) remains very poor, and there is an urgent clinical need to investigate novel therapies for ATL. The expression of phosphatidylinositol 3-kinase-δ (PI3k-δ) is normally restricted to hematopoietic cells and is known as a key determinant of cell survival in certain cancers. The inhibitor of PI3k-δ, idelalisib, has been shown to be effective in the treatment of chronic lymphocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0138-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052569PMC
July 2018
2 Reads

Fibronectin protein expression in renal cell carcinoma in correlation with clinical stage of tumour.

Biomark Res 2018 11;6:23. Epub 2018 Jul 11.

1Department of Urology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, Kerala India.

Background: Carcinogenesis is a multistep process which involves interplay between the tumour cells and the matrix proteins. This occurs by adherence between the tumour cells and proteins in the extracellular matrix. VHL mutation affects through the hypoxia inducible factor (HIF) and causes changes in various tissue proteins like VEGF, PDGF, TGF, Fibronectin and others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0137-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042246PMC
July 2018
1 Read

Kinomic profiling of glioblastoma cells reveals PLCG1 as a target in restricted glucose.

Biomark Res 2018 14;6:22. Epub 2018 Jun 14.

1Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294 USA.

Background: For glioblastoma (GBM) treatments to be effective in vivo, understanding the effects of the tumor microenvironment is imperative. In traditional cell culture conditions, glucose concentrations do not model physiologic levels, nor the diminished concentrations found in tumor niches. We therefore sought to profile the differences in kinase activity in GBM cells cultured in restricted glucose to identify pathways that could be targeted with small molecule inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0136-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001119PMC
June 2018
20 Reads

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes.

Biomark Res 2018 14;6:21. Epub 2018 Jun 14.

1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Chemerin is a recently discovered adipokine shown to be involved in both inflammatory and metabolic processes. Here, we demonstrate that chemerin serum levels are elevated in patients with multiple myeloma and that it increases with disease progression. We found that chemerin is expressed by stromal cells and preadipocytes, whereas its receptor CCRL2 is expressed by primary myeloma cells, suggesting a paracrine signaling loop between bone marrow stromal cells/adipocytes and myeloma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0134-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001014PMC
June 2018
6 Reads

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy.

Biomark Res 2018 14;6:20. Epub 2018 Jun 14.

Departamento de Radiologia e Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, CEP 01246-000, Av. Dr. Arnaldo, São Paulo, SP 251 Brazil.

Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0135-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001168PMC
June 2018
5 Reads

microRNA based prognostic biomarkers in pancreatic Cancer.

Biomark Res 2018 21;6:18. Epub 2018 May 21.

1Stony Brook University, Stony Brook, New York, 11794 USA.

Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0131-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963153PMC
May 2018
1 Read

Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses.

Biomark Res 2018 13;6:17. Epub 2018 Jun 13.

1Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada.

Background: Colorectal cancer has significant impact on individuals and healthcare systems. Many genes have been identified to influence its pathogenesis. However, the genetic basis of mucinous tumor histology, an aggressive subtype of colorectal cancer, is currently not well-known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0133-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998544PMC
June 2018
8 Reads

Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2 mice and mouse mesothelioma cell lines from various mouse strains.

Biomark Res 2018 6;6:19. Epub 2018 Jun 6.

1Anatomy, Section of Medicine, University of Fribourg, Route Albert-Gockel 1, CH-1700 Fribourg, Switzerland.

Background: Calretinin is the most widespread positive marker for the immunohistochemical identification of malignant mesothelioma (MM) and was proposed to serve as a blood-based biomarker. Functionally, evidence has accumulated that calretinin might be implicated in MM tumorigenesis. We aimed to identify calretinin (CR; ) in murine MM and reactive mesothelial cells in granuloma from asbestos-exposed NF2 mice, a line heterozygous for the tumor suppressor merlin (NF2), used as a mouse MM model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0132-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989366PMC
June 2018
2 Reads

Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline mutation.

Biomark Res 2018 11;6:16. Epub 2018 May 11.

2Department of Haematology-Oncology, National University Cancer Institute, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Singapore, 119228 Singapore.

Background: Germline mutations in the transcription factor give rise to a rare autosomal dominant genetic condition classified under the entity: Familial Platelet Disorders with predisposition to Acute Myeloid Leukaemia (FPD/AML). While several studies have identified a myriad of germline RUNX1 mutations implicated in this disorder, second-hit mutational events are necessary for patients with hereditary thrombocytopenia to develop full-blown AML. The molecular picture behind this process remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0130-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948813PMC
May 2018
9 Reads

NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors.

Biomark Res 2018 18;6:15. Epub 2018 Apr 18.

4Medical Oncology, University of Vermont Medical Center, Burlington, VT USA.

Background: Well-differentiated neuroendocrine tumors (NET) most frequently arise from the gastrointestinal tract (GI), pancreas, and lung. Patients often present as metastasis with an unknown primary, and the clinical management and outcome depend on multiple factors, including the accurate diagnosis with the tumor primary site. Determining the site of the NET with unknown primary remains challenging. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-018-0129-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907358PMC
April 2018
14 Reads

PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge.

Biomark Res 2018 11;6:14. Epub 2018 Apr 11.

1Division of Infection, Immunity & Respiratory Medicine, The Medicines Evaluation Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Background: Inhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated protein kinase (p38) and Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling pathways. The activation of these pathways following allergen exposure in atopic asthma patients it is not known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0128-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896031PMC

Diagnosis of GATA2 haplo-insufficiency in a young woman prompted by pancytopenia with deficiencies of B-cell and dendritic cell development.

Biomark Res 2018 21;6:13. Epub 2018 Mar 21.

3Winship Cancer Institute, Emory University, Atlanta, GA 30322 USA.

Background: GATA2 deficiency presents with a spectrum of phenotypes including increased susceptibility to viral and bacterial infections, multi-lineage cytopenias, aplastic anemia, leukemic transformation and lymphedema. Allogeneic transplantation is only curative therapy for GATA2 deficiency, but is associated with significant treatment related morbidity and mortality. Given the spectrum of clinical presentation, accurate diagnosis of GATA2 deficiency is necessary to identify patients early in their disease course when allogeneic bone marrow transplantation may be of clinical benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0127-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863442PMC
March 2018
8 Reads

Erythrocyte fatty acid profiles in children are not predictive of autism spectrum disorder status: a case control study.

Biomark Res 2018 14;6:12. Epub 2018 Mar 14.

1Department of Chemical & Biological Engineering, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, 12180 NY USA.

Biomarkers promise biomolecular explanations as well as reliable diagnostics, stratification, and treatment strategies that have the potential to help mitigate the effects of disorders. While no reliable biomarker has yet been found for autism spectrum disorder (ASD), fatty acids have been investigated as potential biomarkers because of their association with brain development and neural functions. However, the ability of fatty acids to classify individuals with ASD from age/gender-matched neurotypical (NEU) peers has largely been ignored in favor of investigating population-level differences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0125-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853097PMC
March 2018
1 Read

Suitability of Yin Yang 1 transcript and protein levels for biomarker studies in B cell non-Hodgkin lymphoma.

Biomark Res 2018 13;6:11. Epub 2018 Mar 13.

Department of Human and Animal Cell Lines, Leibniz-Institute DSMZ, German Collection of Microorganisms and Cell Cultures, Inhoffenstrasse 7 B, 38124 Braunschweig, Germany.

Background: Yin Yang 1 (YY1) is a transcription factor that plays an important role during all stages of B cell differentiation. Several studies reported upregulation of YY1 in B cell derived lymphoma, indicating that it might act as an oncogene. Furthermore, aberrant YY1 expression has been associated with survival in some entities of B cell non-Hodgkin lymphoma (B-NHL), suggesting that YY1 could be a valuable biomarker in B-NHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0126-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850914PMC

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.

Biomark Res 2018 9;6:10. Epub 2018 Mar 9.

1Department of Medical Oncology, Fudan University Shanghai Cancer Center, No.270, Dongan Road, Shanghai, 200032 China.

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a catalytic component of PRC2, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 also functions both as a transcriptional suppressor and a transcriptional co-activator, depending on H3K27me3 or not and on the different cellular contexts. Unsurprisingly, numerous studies have highlighted the role of EZH2 in cancer development and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0122-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845366PMC
March 2018
5 Reads

Correction to: Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.

Biomark Res 2018 7;6. Epub 2018 Mar 7.

1Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585 Japan.

[This corrects the article DOI: 10.1186/s40364-017-0099-2.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0124-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842620PMC

Protein kinase inhibitors for acute leukemia.

Biomark Res 2018 13;6. Epub 2018 Feb 13.

Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Institute of Laboratory Medicine, Guangdong Medical University, Dongguan, 523808 China.

Conventional treatments for acute leukemia include chemotherapy, radiation therapy, and intensive combined treatments (including bone marrow transplant or stem cell transplants). Novel treatment approaches are in active development. Recently, protein kinase inhibitors are on clinical trials and offer hope as new drugs for acute leukemia treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0123-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809833PMC
February 2018
9 Reads

Acute myeloid leukemia in a father and son with a germline mutation of .

Biomark Res 2018 13;6. Epub 2018 Feb 13.

Emerge Laboratories, Suffern, USA.

Background: Myelodysplastic syndromes and acute myeloid leukemia usually occur sporadically in older adults. More recently cases of familial acute myeloid leukemia and/or myelodysplastic syndrome have been reported.

Case Presentation: Currently we report a father and son who both developed myelodysplastic syndrome that progressed to acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0121-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809979PMC
February 2018
2 Reads

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice.

Biomark Res 2018 5;6. Epub 2018 Feb 5.

1Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.

Background: Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL).

Methods: In this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0120-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800079PMC
February 2018
6 Reads

Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort.

Biomark Res 2018 22;6. Epub 2018 Jan 22.

1Medical Genome Center, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi 474-8511 Japan.

Background: Alzheimer's disease (AD) is a most common dementia in elderly people. Since AD symptoms resemble those of other neurodegenerative diseases, including idiopathic normal pressure hydrocephalus (iNPH), it is difficult to distinguish AD from iNPH for a precise and early diagnosis. iNPH is caused by the accumulation of cerebrospinal fluid (CSF) and involves gait disturbance, urinary incontinence, and dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0119-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778653PMC
January 2018
10 Reads

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Biomark Res 2018 22;6. Epub 2018 Jan 22.

Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853 China.

Severe cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T cell (CAR-T) therapy can be life-threatening in some cases, and management of those toxicities is still a great challenge for physicians. Researchers hope to understand the pathophysiology of CRS and neurotoxicity, and identify predictive biomarkers that can forecast those toxicities in advance. Some risk factors for severe CRS and/or neurotoxicity including patient and treatment characteristics have been identified in multiple clinical trials of CAR-T cell therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0116-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778792PMC
January 2018

Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study.

Biomark Res 2018 12;6. Epub 2018 Jan 12.

2Program of Applied Translational Research, Yale University School of Medicine and VA Medical Center, 60 Temple Street, Suite 6C, New Haven, CT 06510 USA.

Background: Acute kidney injury (AKI) is a frequent complication of cardiac surgery. We sought prognostic combinations of postoperative biomarkers measured within 6 h of surgery, potentially in combination with cardiopulmonary bypass time (to account for the degree of insult to the kidney). We used data from a large cohort of patients and adapted methods for developing biomarker combinations to account for the multicenter design of the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0117-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767010PMC
January 2018
16 Reads

Platelet protein biomarker panel for ovarian cancer diagnosis.

Biomark Res 2018 12;6. Epub 2018 Jan 12.

3Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institute, SE-171 76 Stockholm, Sweden.

Background: Platelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers.

Methods: Two-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest.

Results: PLS-DA of platelet protein expression in 2D gels suggested differences between the International Federation of Gynaecology and Obstetrics (FIGO) stages III-IV of ovarian cancer, compared to benign adnexal lesions with a sensitivity of 96% and a specificity of 88%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-018-0118-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767003PMC
January 2018
7 Reads

SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis.

Authors:
Jianchang Yang

Biomark Res 2018 3;6. Epub 2018 Jan 3.

Department of Surgery and Medicine, Baylor College of Medicine, Houston, TX 77030 USA.

In recent years, there has been substantial progress in our knowledge of the molecular pathways by which stem cell factor SALL4 regulates the embryonic stem cell (ESC) properties, developmental events, and human cancers. This review summarizes recent advances in the biology of SALL4 with a focus on its regulatory functions in normal and leukemic hematopoiesis. In the normal hematopoietic system, expression of SALL4 is mainly enriched in the bone marrow hematopoietic stem/progenitor cells (HSCs/HPCs), but is rapidly silenced following lineage differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0115-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751604PMC
January 2018
2 Reads

Interleukin-10 and soluble tumor necrosis factor receptor II are potential biomarkers of infections in pregnant women: a case-control study from Nanoro, Burkina Faso.

Biomark Res 2017 13;5:34. Epub 2017 Dec 13.

Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands.

Background: Diagnosis of malaria in pregnancy is problematic due to the low sensitivity of conventional diagnostic tests (rapid diagnostic test and microscopy), which is exacerbated due to low peripheral parasite densities, and lack of clinical symptoms. In this study, six potential biomarkers to support malaria diagnosis in pregnancy were evaluated.

Methods: Blood samples were collected from pregnant women at antenatal clinic visits and at delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0114-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729512PMC
December 2017
10 Reads

mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.

Biomark Res 2017 6;5:33. Epub 2017 Dec 6.

Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.

Myelodysplasia (MDS) /myeloproliferative neoplasm (MPN) overlap syndrome has been described since the 2001 WHO classification as disorders that have both proliferative and dysplastic changes simultaneously. Specific disorders include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL negative atypical chronic myeloid leukemia (aCML) and unclassifiable MDS/MPN (MPN/MDS-U). Recurrent gene mutations in these conditions have been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0113-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718013PMC
December 2017
19 Reads

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Biomark Res 2017 10;5:32. Epub 2017 Nov 10.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.

Background: Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the identification of biomarkers is critical for the selection and management of patients receiving treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0112-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681837PMC
November 2017
8 Reads

Critical appraisal of the role of serum albumin in cardiovascular disease.

Biomark Res 2017 10;5:31. Epub 2017 Nov 10.

Cardiovascular Division, Department of Internal Medicine, MacKay Memorial Hospital, Mackay Medical College, No. 92, Sec. 2, Zhongshan N. Rd, Taipei City, 10449 Taiwan, Republic of China.

Concentration of serum albumin (SA), a multifunctional circulatory protein, is influenced by several factors, including its synthesis rate, catabolism rate, extravascular distribution, and exogenous loss. Moreover, both nutritional status and systemic inflammation affect the synthesis of SA. Determining SA concentration aids in risk prediction in various clinical settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0111-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681838PMC
November 2017
3 Reads

Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.

Biomark Res 2017 17;5:30. Epub 2017 Oct 17.

Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Palo Alto, CA 94304 USA.

Background: Quantitative proteomics allows for the discovery and functional investigation of blood-based pre-diagnostic biomarkers for early cancer detection. However, a major limitation of proteomic investigations in biomarker studies remains the biological and technical variability in the analysis of complex clinical samples. Moreover, unlike 'omics analogues such as genomics and transcriptomics, proteomics has yet to achieve reproducibility and long-term stability on a unified technological platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-017-0110-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645980PMC
October 2017
15 Reads